


ACTIVITY REPORT

For the second quarter
of 2018



TCHAIKAPHARMA
HIGH QUALITY MEDICINES

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.

27.07.2018

General information about Tchaikapharma High Quality Medicines Inc.

History and development of Tchaikapharma High Quality Medicines Inc.

Legal and commercial name

The legal and commercial name of the company is Tchaikapharma High Quality Medicines Inc.

Location and registration. Unique Identification Code (UIC)

The Company was listed in the Commercial Registry by Decision from 14.03.2000 on the company case 1096/2000 of the Varna District Court as a joint stock company named TCHAIKA PHARMA INC.

By decision of the General Meeting of Shareholders from 04.07.2003, entered by Decision from 30.07.2003 on the company case 1096/2000 of the Varna District Court, the name was changed to TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.

The Company is listed in the Commercial Register of the Registry Agency at the Ministry of Justice with **UIC 103524525**.

Foundation date and duration in time

The Company was founded and entered in the Commercial Registry by Decision from 14.03.2000 on the company case 1096/2000 of the Varna District Court as a joint stock company. The duration of the Company is not limited in time.

Country of Company registration, headquarters and address pursuant to the Statute; legal form; legislation under which the Company operates

Tchaikapharma High Quality Medicines Inc. is a joint stock company which operates in compliance with the legislation of the Republic of Bulgaria.

The Company was incorporated in the Republic of Bulgaria.

The headquarters and registered office of the Company:

Republic of Bulgaria, 1172 Sofia, 1 G.M. Dimitrov Blvd.

Contact Address: 1172 Sofia, 1 G.M. Dimitrov Blvd.

Telephone: (359 2) 960 3634

Internet site: www.tchaikapharma.com

Important events in the development of the business of the Company

Important events in the development of the Issuer for the last three years:

- Tchaikapharma High Quality Medicines Inc. was not transformed.
- Tchaikapharma High Quality Medicines Inc. was not transferred or pledged.
- There were no significant changes in the scope of activity of Tchaikapharma High Quality Medicines Inc.
- There were no filed claims for opening of insolvency proceedings.
- By Decision of the General Meeting of 20.04.2015 the capital was increased from BGN 43 500 000 to BGN 49 600 000, by issuing 6 100 000 (six million and one hundred thousand) new ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out by capitalization of profits pursuant to Art. 197 of the Commerce Act.
- By Decision of the General Meeting of 23.06.2016 the capital was increased from BGN 49 600 000 to BGN 56 600 000, by issuing 7 000 000 (seven million) new ordinary shares with a nominal value of BGN 1 (one). The increase of the capital was done by capitalization of profits pursuant to Art. 197 of the Commercial Code. The capital increase was entered in the Commercial Register of 19.07.2016
- The current capital of the Company is BGN 56 600 000 distributed in 56 600 000 ordinary dematerialized voting shares with a par value of BGN 1 (one) each.
- By Decision of the General Meeting of 08.06.2017 the capital was increased from BGN 56 600 000 to BGN 64 300 000 by issuing 7 700 000 (seven million and seven hundred thousand) new ordinary dematerialized shares with a nominal value of BGN 1 (one). The increase of the capital was done by capitalization of profits pursuant to Art. 197 of the Commercial Code. The capital increase was entered in the Commercial Register on 05.07.2017.
- By Decision of the General Meeting of 30.04.2018 the capital was increased from BGN 64 300 000 to BGN 72 200 000 by issuing 7 900 000 (seven million and nine hundred thousand) new ordinary dematerialized shares with a nominal value of BGN 1 (one).
-

Tchaikapharma High Quality Medicines Inc. is one of the fastest growing Bulgarian company specialized in manufacturing high quality and affordable generic and original medicines. The production facilities of the company are built in accordance with European requirements. The company is focused of quality and safety of the production of medicinal products for human medicine. In the years in which the company has been on the market it has proved its honesty and patient care. In the second quarter of 2018 Tchaikapharma continued to update its product range, which at this stage is over 150 medicinal products. Its main goal is the renewal of current trends in the worldwide drug therapy. The main priority for the company are medicinal products for the treatment of diabetes, diseases of the central nervous system, cancers and it is mainly focused on medications associated with the treatment of cardiovascular diseases.

Investments

Major investments for each of the following financial years: 2015, 2016 and 2017.

Overview of the investments in fixed assets by type and year is presented in the following table.

Investments for the period	2015	2016	2017
Tchaikapharma High Quality Medicines Inc.			
I. Fixed tangible assets	2 906	1 331	2 762
1. Plant, property and equipment	2 782	1 312	2 760
2. Other fixed assets	124	19	2
II. Fixed intangible assets	532	547	743
1. Industrial property rights	531	495	726
2. Software	1	9	4
3. Patents and licenses		43	43
Total amount of acquisition of fixed tangible and intangible assets	3 438	1 878	3 505

Major investments in progress

The investments in the two factories of Tchaikapharma High Quality Medicines Inc. are the system of serialization and tamper evidence with which we meet the requirements of the European **Directive 2011/62/EU**. From 9.02.2019 every package of a medicinal product can be marketed within the EU with unique coding and tamper evidence. The system will be implemented in cooperation with SoftGroup AD and for installation are planned 5 machines for printing and verification of 2D matrix code (with the unique code of the box) tamper evidence system in each cartoning machine, server: central and local, software for generating individual codes, storing and sending them to the European hub.

A small investment in the plant in Plovdiv is the system for optimizing the energy costs for heating and cooling of the production ventilation system.

Economic activity

The entered in the Commercial Register activity of the Company is: purchase of substances and formulations for the production and sale of pharmaceuticals in finished or

processed form, (after Marketing Authorisation); primary and secondary packaging of formulations (after Marketing Authorisation); import, export, re-export and merchandising in original or processed form; barter transactions and commissions; commercial representation of foreign and domestic individuals and legal entities at home and abroad; industrial and commercial management; consulting, marketing, brokerage, leasing, licensing, entrepreneurship, transport and shipping, research and development activities.

Currently the main scope of activity of the Company can be summarized as follows:

- Production
- Packaging (primary and secondary)
- Marketing and promotion of medicines
- Research and Development

In the second quarter of 2018 Tchaikapharma continued to be one of the leading pharmaceutical companies in Bulgaria, which continued to add new products to its diverse portfolio. The company received a Marketing Authorization for the medicinal product Pizona Combi 15 mg/850 mg film-coated tablets, which controls the level of blood sugar in type 2 diabetes.

Audits of new dossiers have been carried out, which will be submitted for registration both in Europe and only for the Bulgarian market.

Tchaikapharma High Quality Medicines Inc. has entered the market in Kosovo where five new products enrich the company's portfolio there, which will be from the cephalosporin group.

Tchaikapharma High Quality Medicines Inc. has continuously maintained its production facilities in accordance with the contemporary European requirements for Good Manufacturing Practice of Medicines. At present, more than 150 medicinal products are neeing produced in the company's plants. The premises and equipment of the plant are in full compliance with the European requirements for the production of sterile medicinal products.

Tchaikapharma High Quality Medicines Inc., as a high-quality manufacturer of medicinal products, began to produce its own dossiers of medicinal products. The dossier of a medicinal product with INN Irbesartan is underway. The necessary documents such as Protocol, Investigator's Brochure, Patient's Clinical Card, etc., required to obtain authorisation to conduct a second clinical trial to demonstrate the bioequivalence of a fixed combination of irbesartan/hydrochlorothiazide with the CoAprovel reference product are under preparation.

The development and validation of methods for investigation of the concentration of drug substances in human plasma is a major task of the bioanalytical laboratory. An important part of the work of the laboratory is the creation of standard operating procedures to ensure the quality of the work and the reliability of the results. Based on the quality system under construction in the bio-analytical laboratory, it will also be possible to initiate a Good laboratory practice (GLP) compliance procedure.

Employees

As of 30.06.2018 the average number of employees in Tchaikapharma High Quality Medicines Inc. was 137 (133 as of 31.12.2017). In the table below detailed information about the employees in the company is provided.

	30.06.2018	Share
Number of employees as of 30.06.2018	137	100%
Higher education	77	56%
Secondary education	59	43%
Primary education	1	1%
Employees under 30 years	39	28%
Employees 31 - 40 years	53	39%
Employees 41 - 50 years.	31	23%
Employees 51 - 60 years.	9	7%
Employees 60+ years	5	4%
Women	56	41%
Men	81	59%

Significant events since the beginning of the year until 30.06.2018

In the second quarter of 2018 there were no significant events.

Key financial indicators

Indicators	01-06/2018 BGN '000	01-06/2017 BGN '000	change %
Sales revenue	18 519	16 591	11.62%
Earnings before interest, taxes and depreciation (EBITDA)	7 173	5 642	27.14%
Net profit	4 899	3 600	36.08%

	01-06/2018 BGN '000	01-12/2017 BGN '000	change %
Non-current assets	34 760	35 762	-2.80%
Current assets	67 201	61 220	9.77%
Equity	87 202	82 303	5.95%

Non-current liabilities	1 849	1 981	-6.66%
Current liabilities	12 910	12 698	1.67%

	01-06/2018	01-06/2017
EBITDA/Sales revenue	39%	34%
Net profit/Sales revenue	26%	22%

Review of the risk factors

- The Company's activities could be affected by any change in the regulatory requirements for the production of pharmaceutical products.
- Changes to the legislation regulating the Company's business are possible, and these can potentially increase the costs of compliance or have another effect on its operations.
- The production processes of the Company are subject to stringent requirements and approvals by regulatory authorities which may delay or interrupt the operations of the Company.
- The ability of the Company to pay dividends depends on a number of factors and there is no guarantee that in a year it will be able to pay dividends in accordance with its dividend policy.
- The Company is exposed to operational risk, which is inherent in its business activities.
- The Company is subject to multitude laws and regulations in the field of environmental protection and health and safety conditions and is exposed to potential liabilities related to the environment.
- The Company is exposed to strong competition.

The Company operates in active exchange with foreign suppliers and customers. It is therefore exposed to currency risk, mainly against the US dollar. Currency risk is related to the adverse movement in the exchange rate of the US dollar against the Bulgarian lev in future business operations, recognized foreign currency assets and liabilities. The rest of the company's operations are usually denominated in Bulgarian lev and/or in euros.

Sales by types of dosage forms

Revenue by dosage forms	01-06/2018 BGN '000	01-06/2017 BGN '000
Tablets	15 632	13 918
Ampules	542	1 065
Vials	2 290	1 531
Total:	18 464	16 514

Revenue by therapeutic groups	01-06/2018	01-06/2017
	BGN '000	BGN '000
Cardiovascular system	13 727	12 737
Musculoskeletal system and connective tissue	62	42
Respiratory system and antibiotics	1 988	1 520
Nervous system	772	676
Endocrine system	670	499
Other products	528	476
Digestive system and metabolism	607	481
Oncology	110	83
Total:	18 464	16 514

Changes in the inventories of products and work in progress

(59) 444

Other operating income

	01-06/2018	01-06/2017
	BGN '000	BGN '000
Income from rent	18	25
Other income	22	52
Total:	40	77

Financial income

	01-06/2017	01-06/2016
	BGN '000	BGN '000
Income from interest	1	-
Income from exchange rate differences	5	65
Other financial income	-	-
Total:	6	65

Core activity expenses

Operating expenses

	01-06/2018	01-06/2017
	BGN '000	BGN '000
Book value of sold products	1 264	764
Materials	4 979	4 671
External services	3 066	3 926
Salaries	1 532	1 355
Social security costs	275	273
Depreciation costs	1 669	1 506
Other	132	426
Total:	12 917	12 921

Cost of materials

01-06/2018 01-06/2017

	BGN '000	BGN '000
Basic material	4 415	4 255
Electricity	200	161
Fuels and lubricants	32	25
Spare parts and laboratory materials	67	101
Water	9	10
Other materials	256	119
Total:	4 979	4 671

Costs of external services	01-06/2018 BGN '000	01-06/2017 BGN '000
Rents	120	106
Security	106	106
Insurance	12	16
Telephone and postage expenses	15	14
Equipment maintenance and subscription	73	56
Fees	46	44
Transport costs	16	30
Other costs for external services	2 678	3 554
Total:	3 066	3 926

Financial expenses	01-06/2018 BGN '000	01-06/2017 BGN '000
Interest expenses	113	136
Expenses on operations with financial instruments	1	
Expenses from exchange rate differences	25	21
Other financial expenses	19	22
Total:	158	179

Assets

Non-current assets	01-06/2018 BGN '000	01-12/2017 BGN '000
Property, plant and equipment	25 712	26 803
Intangible assets	3 087	2 998
Investments with minority interest	1	1
Trade receivables	5 960	5 960
Total non-current assets	34 760	35 762

Current assets	01-06/2018 BGN '000	01-12/2017 BGN '000
Inventories	4 374	5 190
Trade and other receivables	62 785	55 998

Treasury shares redeemed	7	8
Cash and cash equivalents	35	24
Total current assets	67 201	61 220
Total Assets	101 961	96 982

	01-06/2018 BGN '000	01-12/2017 BGN '000
Property, plant and equipment		
Land and buildings	11 458	11 676
Machinery and equipment	12 220	13 076
Other	155	191
In the process of acquisition	1 879	1 860
	25 712	26 803

	01-06/2018 BGN '000	01-12/2017 BGN '000
Inventories		
Materials	3 729	4 384
Production	472	542
Goods	130	229
Work in progress	43	35
Total:	4 374	5 190

Equity and liabilities

	01-06/2018 BGN '000	01-12/2017 BGN '000
Registered capital	72 200	64 300
Statutory reserve	10 103	9 172
Undistributed profit	4 899	8 831
Total Equity	87 202	82 303

	01-06/2018 BGN '000	01-12/2017 BGN '000
Liabilities		
Non-current liabilities		
Long-term loans	458	590
Deferred tax liabilities	1 308	1 308
Liabilities to employees on retirement	83	83
Total non-current liabilities	1 849	1 981

Current liabilities		
Trade and other liabilities	2 456	2 134
Short term loans	9 778	9 784
Current part of long-term loans	374	491
Current corporate income tax		78
Other tax liabilities	302	211
Total current liabilities	12 910	12 698

Total liabilities	14 759	14 679
Total equity and liabilities	101 961	96 982

Financial indicators

01-06/2018 01-12/2017

Debt ratio	0.17	0.18
Financial autonomy ratio	5.91	5.61

Information on the shares of Tchaikapharma High Quality Medicines Inc.

The total amount of shares issued as of 30.06.2018 was 72 200 000 with a nominal value of BGN 1 per share. All issued shares are registered, dematerialized, ordinary and indivisible under the Statute of the Company. All issued shares are of the same type. Each share gives equal rights to its owner in proportion to the nominal value of the share. The shares of Tchaikapharma High Quality Medicines Inc. are traded on the official market of the Bulgarian Stock Exchange-Sofia.

Essential information on the shares of Tchaikapharma High Quality Medicines Inc.

	1-06/2018	1-06/2017
Total number of issued shares	72 200 000	56 600 000
Number of shares in circulation at end of period	72 200 000	56 600 000
Price per share at the end of the period in BGN	8.10	7.46
Market capitalization at the end of the period in BGN	584 820 000	422 236 000

Biser Georgiev

/Executive Director/

